Use of vivo-morpholinos for control of protein expression in the adult rat brain

Kathryn J. Reissner, Gregory Sartor, Elena M. Vazey, Thomas E. Dunn, Gary Aston-Jones, Peter W. Kalivas

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Vivo-morpholinos are commercially available morpholino oligomers with a terminal octa-guanidinium dendrimer for enhanced cell-permeability. Existing evidence from systemically delivered vivo-morpholinos indicate that genetic suppression can last from days to weeks without evidence of cellular toxicity. However, intravenously delivered vivo-morpholinos are ineffective at protein suppression in the brain, and no evidence is available regarding whether intracranially delivered vivo-morpholinos effectively reduce target protein levels, or do so without inducing neurotoxicity. Here we report examples in which in vivo microinjection of antisense vivo-morpholinos directed against three different targets (xCT, GLT1, orexin) in two different brain regions resulted in significant suppression of protein expression without neurotoxicity. Expression was significantly suppressed at six to seven days post-administration, but returned to baseline levels within fourteen days. These results indicate that direct intracranial administration of vivo-morpholinos provides an effective means by which to suppress protein expression in the brain for one to two weeks.

Original languageEnglish (US)
Pages (from-to)354-360
Number of pages7
JournalJournal of Neuroscience Methods
Volume203
Issue number2
DOIs
StatePublished - Jan 30 2012
Externally publishedYes

Fingerprint

Morpholinos
Brain
Proteins
Genetic Suppression
Dendrimers
Guanidine
Microinjections
Permeability

Keywords

  • Antisense
  • GLT-1
  • Hypocretin
  • Lateral hypothalamus
  • Nucleus accumbens
  • Orexin
  • Vivo-morpholino
  • XCT

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Reissner, K. J., Sartor, G., Vazey, E. M., Dunn, T. E., Aston-Jones, G., & Kalivas, P. W. (2012). Use of vivo-morpholinos for control of protein expression in the adult rat brain. Journal of Neuroscience Methods, 203(2), 354-360. https://doi.org/10.1016/j.jneumeth.2011.10.009

Use of vivo-morpholinos for control of protein expression in the adult rat brain. / Reissner, Kathryn J.; Sartor, Gregory; Vazey, Elena M.; Dunn, Thomas E.; Aston-Jones, Gary; Kalivas, Peter W.

In: Journal of Neuroscience Methods, Vol. 203, No. 2, 30.01.2012, p. 354-360.

Research output: Contribution to journalArticle

Reissner, KJ, Sartor, G, Vazey, EM, Dunn, TE, Aston-Jones, G & Kalivas, PW 2012, 'Use of vivo-morpholinos for control of protein expression in the adult rat brain', Journal of Neuroscience Methods, vol. 203, no. 2, pp. 354-360. https://doi.org/10.1016/j.jneumeth.2011.10.009
Reissner, Kathryn J. ; Sartor, Gregory ; Vazey, Elena M. ; Dunn, Thomas E. ; Aston-Jones, Gary ; Kalivas, Peter W. / Use of vivo-morpholinos for control of protein expression in the adult rat brain. In: Journal of Neuroscience Methods. 2012 ; Vol. 203, No. 2. pp. 354-360.
@article{f9aab9c6270643e2abf50c0f255e1bae,
title = "Use of vivo-morpholinos for control of protein expression in the adult rat brain",
abstract = "Vivo-morpholinos are commercially available morpholino oligomers with a terminal octa-guanidinium dendrimer for enhanced cell-permeability. Existing evidence from systemically delivered vivo-morpholinos indicate that genetic suppression can last from days to weeks without evidence of cellular toxicity. However, intravenously delivered vivo-morpholinos are ineffective at protein suppression in the brain, and no evidence is available regarding whether intracranially delivered vivo-morpholinos effectively reduce target protein levels, or do so without inducing neurotoxicity. Here we report examples in which in vivo microinjection of antisense vivo-morpholinos directed against three different targets (xCT, GLT1, orexin) in two different brain regions resulted in significant suppression of protein expression without neurotoxicity. Expression was significantly suppressed at six to seven days post-administration, but returned to baseline levels within fourteen days. These results indicate that direct intracranial administration of vivo-morpholinos provides an effective means by which to suppress protein expression in the brain for one to two weeks.",
keywords = "Antisense, GLT-1, Hypocretin, Lateral hypothalamus, Nucleus accumbens, Orexin, Vivo-morpholino, XCT",
author = "Reissner, {Kathryn J.} and Gregory Sartor and Vazey, {Elena M.} and Dunn, {Thomas E.} and Gary Aston-Jones and Kalivas, {Peter W.}",
year = "2012",
month = "1",
day = "30",
doi = "10.1016/j.jneumeth.2011.10.009",
language = "English (US)",
volume = "203",
pages = "354--360",
journal = "Journal of Neuroscience Methods",
issn = "0165-0270",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Use of vivo-morpholinos for control of protein expression in the adult rat brain

AU - Reissner, Kathryn J.

AU - Sartor, Gregory

AU - Vazey, Elena M.

AU - Dunn, Thomas E.

AU - Aston-Jones, Gary

AU - Kalivas, Peter W.

PY - 2012/1/30

Y1 - 2012/1/30

N2 - Vivo-morpholinos are commercially available morpholino oligomers with a terminal octa-guanidinium dendrimer for enhanced cell-permeability. Existing evidence from systemically delivered vivo-morpholinos indicate that genetic suppression can last from days to weeks without evidence of cellular toxicity. However, intravenously delivered vivo-morpholinos are ineffective at protein suppression in the brain, and no evidence is available regarding whether intracranially delivered vivo-morpholinos effectively reduce target protein levels, or do so without inducing neurotoxicity. Here we report examples in which in vivo microinjection of antisense vivo-morpholinos directed against three different targets (xCT, GLT1, orexin) in two different brain regions resulted in significant suppression of protein expression without neurotoxicity. Expression was significantly suppressed at six to seven days post-administration, but returned to baseline levels within fourteen days. These results indicate that direct intracranial administration of vivo-morpholinos provides an effective means by which to suppress protein expression in the brain for one to two weeks.

AB - Vivo-morpholinos are commercially available morpholino oligomers with a terminal octa-guanidinium dendrimer for enhanced cell-permeability. Existing evidence from systemically delivered vivo-morpholinos indicate that genetic suppression can last from days to weeks without evidence of cellular toxicity. However, intravenously delivered vivo-morpholinos are ineffective at protein suppression in the brain, and no evidence is available regarding whether intracranially delivered vivo-morpholinos effectively reduce target protein levels, or do so without inducing neurotoxicity. Here we report examples in which in vivo microinjection of antisense vivo-morpholinos directed against three different targets (xCT, GLT1, orexin) in two different brain regions resulted in significant suppression of protein expression without neurotoxicity. Expression was significantly suppressed at six to seven days post-administration, but returned to baseline levels within fourteen days. These results indicate that direct intracranial administration of vivo-morpholinos provides an effective means by which to suppress protein expression in the brain for one to two weeks.

KW - Antisense

KW - GLT-1

KW - Hypocretin

KW - Lateral hypothalamus

KW - Nucleus accumbens

KW - Orexin

KW - Vivo-morpholino

KW - XCT

UR - http://www.scopus.com/inward/record.url?scp=82055165305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82055165305&partnerID=8YFLogxK

U2 - 10.1016/j.jneumeth.2011.10.009

DO - 10.1016/j.jneumeth.2011.10.009

M3 - Article

C2 - 22027492

AN - SCOPUS:82055165305

VL - 203

SP - 354

EP - 360

JO - Journal of Neuroscience Methods

JF - Journal of Neuroscience Methods

SN - 0165-0270

IS - 2

ER -